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ABSTRACT
First described in 1985, intermediate cell histiocytosis is a rare disorder of the cutaneous dendritic cell group with a varied 
clinical presentation and evolution. The pathologic substrate is constituted by the proliferation of indeterminate cells (ICs) 
that are immunophenotypically characterized by the positivity of CD1a, CD68, and faint/focal S100, plus the negativity 
for CD207 (langerin). The authors present the case of a healthy elderly woman who presented generalized dome-shaped 
reddish cutaneous nodules over her trunk, neck, face, and extremities over a period of 18 months. A laboratory and 
imaging work-up ruled out internal involvement. The skin biopsy was consistent with IC histiocytosis. The patient was 
treated with narrowband ultraviolet B phototherapy, which resulted in an excellent short-term outcome. 
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CASE REPORT
A 76-year-old Caucasian woman sought medical 
care complaining of the presence of scattered nodules 
all over her body surface. She referred the onset of 
the appearance of a few dispersed lesions on the 
neck 18 months before. Since then, new lesions had 
appeared in the inframammary region, abdomen, and 
back, which centrifugally spread to the lower and 
upper limbs, and finally to the face involving the nose 
and ears. The patient was reluctant to seek medical 
care until the lesions began to appear in exposed 
areas, especially on her face. During this period, she 
maintained in good health.
She had recently used a corticoid cream over 
her face with subjective improvement. She denied 
fever, weight loss, or any other complaint except for 
hopelessness caused by her appearance. Her medical 
history included the diagnosis of hypertension and the 
regular use of valsartan, levanlodipine, clopidogrel, 
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and simvastatin; she also had a myocardial infarction 
10 years ago, which had been treated with an 
angioplasty. The physical examination showed an 
apparently depressed patient, weighing 78 kg, with 
a height of 1.58 m, and normal vital signs. The skin 
examination revealed multiple reddish or brown 
dome-shaped, non-pruriginous, painless papules 
of varying sizes (1-5 mm) of firm consistency that 
eventually ulcerated (Figure 1). The remaining 
examination was normal.
The laboratory work-up, which included a total 
blood cell count and erythrocyte sedimentation 
rate, electrolytes, renal function tests, calcium, 
hepatic enzymes, uric acid, thyroid function, protein 
electrophoresis, β2 microglobulin, and immunoglobulin 
dosage, was within the normal range. Serology for 
HIV1 and HIV2, hepatitis B, hepatitis C, syphilis, 
antinuclear antibody, and anti-DNA were negative. 
A bone radiological inventory ruled out any lesion. 
A thoracic tomography disclosed signs consistent 
with pulmonary emphysema. The positron emission 
tomography-computed tomography scans showed 
multiple hypermetabolic cutaneous lesions, but no 
other suspicious lesions were described. The magnetic 
resonance imaging showed no evidence of central 
nervous system disease. Therefore, she was deemed 
free of internal disease.
The patient was submitted to a skin biopsy, 
which revealed a dense superficial dermal infiltrate 
composed of histiocytoid cells with oval-shaped nuclei 
sometimes presenting longitudinal chromatin grooves. 
Sparse multinucleated cells and plasma cells were 
also present. Small lymphocytes surrounded groups 
of histiocytes. The epidermis showed spongiosis, 
lymphocytes exocytosis, and a focally ulcerated area 
(Figures 2A, B). Immunostains were focally positive 
for S100 (Figure 2C) and CD68 (Figure 2D); diffusely 
positive for CD1a (Figures 3A, B) and were negative for 
CD207 (langerin) (Figure 3C). The Ki67 labeling index 
was about 60% (Figure 3D). Based on these findings, 
the diagnosis was concluded as an indeterminate 
dendritic cell tumor; also called indeterminate cell (IC) 
histiocytosis. The BRAF V600 mutation was negative in 
the neoplastic cells (sequencing analysis of BRAF gene 
mutations technique).
With the diagnosis of IC histiocytosis of exclusive 
cutaneous involvement (single multifocal system), 
corticosteroid (prednisone 0.5 mg/kg/day) was started 
but the patient’s blood pressure increased. Muscular 
pain and headache ensued and another treatment 
modality needed to be scheduled. Taking into 
account the patient’s intolerance to the intermediate 
steroids dose, age, and comorbidities, a reasonable 
option was local therapy, so the patient was treated 
with narrowband ultraviolet B (UVB) phototherapy 
three times a week for 2 months. The lesions started 
effacing after the first month of the phototherapy and 
completely subsided on the third month leaving local 
hyperpigmentation. The patient is now at the sixth 
month of follow-up and is completely symptomless 
(Figure 4); she did not report any adverse reactions.
DISCUSSION
Histiocytoses comprise a group of disorders 
characterized by the proliferation of monocytes, 
macrophages, and dendritic cells, which are not involved 
Figure 1. Skin examination showing in A - disseminated 
nodular lesions over the face; B - over the trunk and the 
inframammary region; C - over the lateral face of the 
thorax; and D - over the back.
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Figure 2. Histology and Immunostains of the skin biopsy. A - Dense infiltrate in the dermis (H&E, 100X); B - Infiltrate 
composed by histiocytoid cells, lymphocytes, plasma cells and multinucleated cells (H&E, 400X); C - S100 partially 
positive in epidermal Langerhans cells and dermal infiltrate (anti-S100, 200X); D - CD68 positive in histiocytoid cells 
of the dermal infiltrate (anti-CD68, 200X).
Figure 3. Photomicrography of the Immunostains of the skin biopsy in A and B - CD1a diffusely positive in dermal 
histiocytoid cells and epidermal Langerhans cells (anti-CD1a, 200X); C - CD207 (Langerin) negative in the demal 
infiltrate and positive in the epidermal Langerhans cells (anti-CD207, 200X); D - Ki67 positive in about 60% of the 
dermal cells infiltrate (anti-Ki67, 400X).
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in a response to primary disease. The nomenclature of 
histiocytosis has changed substantially over the last half 
century, which is now based on the primary involved 
cell in the pathophysiology of the disease.
The bone marrow pluripotent stem cells, under 
the influence of (i) granulocyte-macrophage colony 
stimulating factor (GM-CSF); and (ii) tumor necrosis 
factor alpha (TNFα) differentiate into a particular 
group of specialized cells with the functions of antigen 
presentation and phagocytosis–the dendritic cells.1 
These cells move into the blood stream and migrate 
to the dermal and epidermal layers of the skin. Within 
the tissue (skin) the dendritic cell precursors under the 
action of the transforming growth factor β1 (TGF-β1) 
develop the Birbeck granules and therefore will 
differentiate into the Langerhans cells. The other cells 
will not suffer the action of such a cytokine and will 
remain as two different populations of dendritic cells.2 
Along with different subpopulations of lymphocytes, 
the epidermal Langerhans cells and other dermal 
antigen-presenting cells (ICs and dendritic cells) 
make up the major component of the skin’s immune 
system. The proliferation of such cells will categorize 
the histiocytoses in (i) Langerhans cell histiocytosis 
(LCH): (ii) non-Langerhans cell histiocytosis (NLCH); and 
(iii) IC histiocytosis (ICH).3 Although the latter has been 
proposed to be a variant of the NLCH,4 in 2008 the 
World Health Organization (WHO) incorporated ICH 
into the tumors of the hematopoietic and lymphoid 
tissue tumors.5
The precise origin of the IC is under debate. While 
some researchers believe that they are precursors 
of Langerhans cells, which, when en route to the 
epidermis, remained arrested into the dermis and did 
not acquire the Birbeck granules,6-8 other researchers 
believe they are “veiled dendritic cells” that migrate 
from the skin to the regional lymph nodes.9 Additionally, 
experimental evidence points toward the myeloid 
lineage for the bone-marrow-derived dendritic cells 
by presenting myeloid lineage markers, such as CD13 
and CD33.10-13
Thus, ICs are dendritic elements of the skin 
(specifically of the dermis, but occasionally the 
epidermis as well), which express CD1a, CD68, and 
feeble S100. The absence of the Birbeck granules–
and therefore the lack of the expression of CD 207 
(langerin)–differentiates IC from Langerhans cells.
In 1985, Wood et al.8 first described the IC 
histiocytosis. Despite being much more common in 
adults,14 ICH has been reported in all ages and no 
gender predominance has been observed. Clinically, 
ICH is characterized by cutaneous (sparing mucosae) 
pinky to reddish, varying sized, non-itchy, painless 
papules or nodules that appear in otherwise healthy 
persons. A reactive form triggered by cutaneous 
diseases, such as scabies and pityriasis rosea, has been 
reported.15,16 Such lesions may be single, a discrete 
group of lesions, or multiple generalized papules 
spread over the trunk, face, and extremities, which 
may present spontaneous remission, stable disease, 
or remission and recurrence.4,9,16-18 The exclusive 
cutaneous presentation is the rule; however, bone 
and corneal involvement have been reported.19,20 
The clinical differential diagnosis of ICH is represented 
by generalized eruptive histiocytosis, a non-Langerhans 
cell histiocytosis, but in this condition the histiocytes 
do not express CD1a and S100 protein. The ICH 
Figure 4. Cutaneous examination after the sixth month 
of therapy. The face is free of lesions - A; and some 
erythematous scar-like lesions remain on the trunk - B, C 
and D.
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histopathological differential diagnosis is represented 
by Langerhans cell histiocytosis where the dendritic cells 
display cytoplasmic Birbeck granules at transmission 
electron microscopy exam and positivity to CD207 
(langerin).
The rarity of this entity imposes certain difficulties 
in establishing any relationship with other malignancies. 
However, concomitant or not, cases of ICH have 
been reported in association with low-grade B-cell 
lymphoma18,21 and other hematologic malignancies 
years after their initial diagnosis.
The optimal treatment for ICH is not clear, but 
similarly to LCH, identifying the initial presentation and 
organ or system involvement is critical for choosing 
the appropriate modality of therapy (a systemic 
work-up prior to the initiation of treatment should 
be considered). Case reports describe a wide range 
of effective therapies that include UVB phototherapy, 
thalidomide, methotrexate, and surgical excision for 
solitary lesions.22,23
As far as we know, based on published data, this 
is the third case treated with narrowband UVB with 
very few side effects, good tolerability, and an excellent 
short-term result.24,25
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